World Health Organization recommends GLP-1 drugs for obesity

Industry Perspective on Obesity Treatment - The World Health Organization (WHO) now recommends GLP-1 drugs like Zepbound and WGOI for adults managing obesity, marking a significant shift in approach [1] - WHO considers these therapies a "scientific breakthrough" but emphasizes they are not a singular solution, advocating for combination with healthy diet and physical activity for long-term treatment [1] - The industry recognizes obesity as a complex disease influenced by genetics, environment, and lifestyle factors, moving away from the idea that it's solely a behavioral failure [3] Cost and Access to Medication - The industry is actively working to improve access to GLP-1 drugs, but commercial insurance coverage and Medicare coverage for obesity remain challenges in the US [3] - Negotiated deals with Lily and Novanorisk are expected to take effect in 2026, with potential price decreases, such as a reduction from $1,000 to $350 per month, but affordability remains a concern for many [5][6] - There is momentum to make these drugs more affordable globally [6] Regulatory and Pricing Landscape - Osmpic and WGO are on the 15-drug list for 2027 under the Inflation Reduction Act, indicating ongoing regulatory and pricing considerations [5]